Venous Thromboembolism in Cancer Patients: Still Looking for Answers

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2019 Dec 11

PMID 31819767

Citations 26

Authors

Roua Anamaria Iorga

Ovidiu Gabriel Bratu

Radu Dragos Marcu

Traian Constantin

Dan Liviu Dorel Mischianu

Bogdan Socea

Mihnea-Alexandru Gaman

Camelia Cristina Diaconu

Affiliations

Soon will be listed here.

Abstract

Patients with cancer-associated venous thromboembolism (VTE) represent a real challenge in clinical practice. Patients with cancer have a greater risk both of VTE and bleeding. There are only a few studies regarding the therapeutic approach of VTE in patients with cancer, especially after cancer surgery, and on thromboprophylaxis during chemotherapy. Many of the anticoagulation therapy recommendations for cancer patients are extrapolated from trials that are not conducted in cancer cohorts. It is essential to assess the efficacy and safety of VTE prophylaxis in this particular subgroup, which bears higher risks both of VTE recurrence and major hemorrhagic events. The introduction of direct oral anticoagulants in everyday practice represented a major evolution of the anticoagulant treatment. Direct anticoagulants could represent a more appealing alternative to low-molecular-weight heparin in paraneoplastic venous thrombosis, due to the patient comfort, easy administration of the drug and emerging studies that prove similar efficacy and safety as the standard treatment. However, there is limited data on the treatment with direct oral anticoagulants in patients with paraneoplastic venous thromboembolism.

Citing Articles

High Rate of Thromboembolic Events in the Last Year of Life of Cancer Patients: A Registry Study.

Strang P, Schultz T Cancers (Basel). 2024; 16(23).

PMID: 39682217 PMC: 11640034. DOI: 10.3390/cancers16234031.

Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients' healthcare in Spain.

Munoz Martin A, Trujillo-Santos A, Marti E, Jara-Palomares L, Macias Montero R, Gallardo E Clin Transl Oncol. 2024; 26(6):1319-1328.

PMID: 38349577 PMC: 11108917. DOI: 10.1007/s12094-023-03379-z.

Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment.

Pavlovic D, Niciforovic D, Markovic M, Papic D Clin Med Insights Oncol. 2023; 17:11795549231220297.

PMID: 38152726 PMC: 10752082. DOI: 10.1177/11795549231220297.

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review.

Gornicki T, Buldys K, Zielinska D, Chabowski M Cancers (Basel). 2023; 15(10).

PMID: 37345034 PMC: 10216040. DOI: 10.3390/cancers15102697.

Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.

Shao Y, Ho C, Chang C, Chang C, Lee J, Lin H Acta Cardiol Sin. 2023; 39(2):242-253.

PMID: 36911539 PMC: 9999188. DOI: 10.6515/ACS.202303_39(2).20220719A.

References

Carrier M, Khorana A, Moretto P, Le Gal G, Karp R, Zwicker J . Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014; 127(1):82-6.e1. DOI: 10.1016/j.amjmed.2013.09.015. View

Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R . Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368(6):513-23. DOI: 10.1056/NEJMoa1111096. View

Rose A, Sharman J, Ozonoff A, Henault L, Hylek E . Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007; 22(7):997-1002. PMC: 2219727. DOI: 10.1007/s11606-007-0228-y. View

Agnelli G, Buller H, Cohen A, Gallus A, Lee T, Pak R . Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015; 13(12):2187-91. DOI: 10.1111/jth.13153. View

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L . Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10):943-9. DOI: 10.1016/S1470-2045(09)70232-3. View

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

Walenga J, Adiguzel C . Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010; 64(7):956-67. DOI: 10.1111/j.1742-1241.2009.02286.x. View

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

Zwicker J, Schlechter B, Stopa J, Liebman H, Aggarwal A, Puligandla M . Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019; 4(4). PMC: 6478409. DOI: 10.1172/jci.insight.125851. View

10.

Solomon I, Voiculescu V, Caruntu C, Lupu M, Popa A, Ilie M . Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember. Dis Markers. 2018; 2018:9787831. PMC: 5966665. DOI: 10.1155/2018/9787831. View

11.

Ibrahim R, Skewes M, Kuriakose P . 'Sailing in troubled waters': a review of the use of anticoagulation in adult cancer patients with thrombocytopenia. Blood Coagul Fibrinolysis. 2016; 27(6):615-30. DOI: 10.1097/MBC.0000000000000539. View

12.

Elting L, Escalante C, Cooksley C, Avritscher E, Kurtin D, Hamblin L . Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164(15):1653-61. DOI: 10.1001/archinte.164.15.1653. View

13.

Sorensen H, Mellemkjaer L, Olsen J, Baron J . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-50. DOI: 10.1056/NEJM200012213432504. View

14.

Prins M, Lensing A, Bauersachs R, van Bellen B, Bounameaux H, Brighton T . Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1):21. PMC: 3850944. DOI: 10.1186/1477-9560-11-21. View

15.

Gross C, Galusha D, Krumholz H . The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med. 2007; 22(3):321-6. PMC: 1824718. DOI: 10.1007/s11606-006-0019-x. View

16.

Agnelli G, George D, Kakkar A, Fisher W, Lassen M, Mismetti P . Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012; 366(7):601-9. DOI: 10.1056/NEJMoa1108898. View

17.

Lee A, Kamphuisen P, Meyer G, Bauersachs R, Janas M, Jarner M . Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015; 314(7):677-686. DOI: 10.1001/jama.2015.9243. View

18.

Khorana A, Noble S, Lee A, Soff G, Meyer G, OConnell C . Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(9):1891-1894. DOI: 10.1111/jth.14219. View

19.

Francis C, Kessler C, Goldhaber S, Kovacs M, Monreal M, Huisman M . Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015; 13(6):1028-35. DOI: 10.1111/jth.12923. View

20.

Akl E, van Doormaal F, Barba M, Kamath G, Kim S, Kuipers S . Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008; 27:4. PMC: 2438335. DOI: 10.1186/1756-9966-27-4. View